ASSESSMENT OF IMMUNOGENICITY OF LIVE ATTENUATED GOATPOX VACCINE AGAINST LUMPY SKIN DISEASE IN CATTLE
| dc.contributor.advisor | DEEPTHI .B (MAJOR) | |
| dc.contributor.advisor | SRIVANI .M | |
| dc.contributor.advisor | SUBHASHINI .N | |
| dc.contributor.author | SAI SINDHU MUMMADISETTY | |
| dc.date.accessioned | 2024-07-08T06:26:08Z | |
| dc.date.available | 2024-07-08T06:26:08Z | |
| dc.date.issued | 2024-03 | |
| dc.description.abstract | Lumpy skin disease (LSD) is a rapidly emerging, transboundary and notifiable disease listed by the World Organization for Animal Health. LSD is being reported regularly with escalated incidence in India ever since its first appearance in 2019. Severe systemic disease is reported in the affected cattle, resulting in devastating economic losses. Mass vaccination of susceptible animals is the foremost approach in tackling infectious diseases. However, several heterologous and homologous vaccines are being used as a prophylactic measure across the globe to control LSD outbreaks. Although the efficacy and immunogenicity of homologous LSD vaccines is known to be excellent, cost of vaccine production along with the Neethling responses observed in the vaccinated animals urged the need for alternative vaccine candidates. Owing to its high degree of co linearity and amino acid identity of LSDV with other Capripoxviruses (CaPVs), heterologous vaccines employing Goatpox vaccines (GPV) and Sheeppox vaccines (SPV) can be safely used to protect against LSDV. The present study deals with an objective to determine the optimum dose of Goatpox vaccine against LSD infections in cattle. A total of 31 samples were collected from clinical cases suspected for LSD, in different areas of Andhra Pradesh during September to December, 2022. Of the 31 samples, 26 were found positive for LSDV by PCR using primers targeting CaPV- specific P32 gene and LSDV- specific RPO30 gene. Clinical samples (n=10) confirmed by PCR were considered for isolation of LSDV in Madin-Darby Bovine Kidney (MDBK) cell line. LSDV (LSDV/Cattle/VJA PNGR/SVVU/2022) could be isolated from two samples (nasal swab and skin scab, both collected from a single clinical case) in the fifth passage showing characteristic cytopathic changes. MDBK amplified virus was adapted to Vero cell line and obtained infectivity titer of 10-7.595 per 100 μL is further employed for use in serum neutralization test. Phylogenetic analysis of the LSDV isolate based on full length ORF036 gene (RPO30) showed 100 % identity and formed a distinct clade with Middle-east Asia and African isolates. Amino acid specific signatures to differentiate CaPVs were noticed and estimates of evolutionary divergence over sequence pairs between clusters was determined that showed a distance of 9.52 % between vaccine strains and the field isolate in the present study. Vaccination trial was conducted in randomly selected heifers placed into four groups (A, B, C and D) of eight animals each. Group A served as control group, while groups B, C and D were vaccinated with 1mL, 2mL and 3mL of 1 X 103.0 TCID50/dose of Goatpox vaccine respectively. Group D vaccinated with 3 times the dose used in goats produced the best humoral immunity that was persistent till the end of the trial i.e., 35 days post vaccination(p<0.05). Thus, this study shows thrice the dose of Goatpox vaccine used in goats is considered as the optimum dose in cattle against LSD. | |
| dc.identifier.uri | https://krishikosh.egranth.ac.in/handle/1/5810211582 | |
| dc.language.iso | English | |
| dc.pages | 139 | |
| dc.publisher | SRI VENKATESWARA VETERINARY UNIVERSITY, TIRUPATI - 517 502. (A.P.) INDIA | |
| dc.sub | Veterinary Microbiology | |
| dc.theme | ASSESSMENT OF IMMUNOGENICITY OF LIVE ATTENUATED GOATPOX VACCINE AGAINST LUMPY SKIN DISEASE IN CATTLE | |
| dc.these.type | M.V.Sc. | |
| dc.title | ASSESSMENT OF IMMUNOGENICITY OF LIVE ATTENUATED GOATPOX VACCINE AGAINST LUMPY SKIN DISEASE IN CATTLE | |
| dc.type | Thesis |